Phaseline

Targets › GCN2

GCN2 (eIF-2-alpha kinase GCN2): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 2 Phase 1; Oncology; next expected readout Nov 2026.

Metabolic-stress sensing protein kinase that phosphorylates the alpha subunit of eukaryotic translation initiation factor 2 (EIF2S1/eIF-2-alpha) in response to low amino acid availability. Plays a role as an activator of the integrated stress response (ISR) required for adaptation to amino acid starvation (By similarity). (UniProt, Q9P2K8)

Open in Phaseline: the race on GCN2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
HiberCellHC-7366
GCN2 kinase activator
GCN2Phase 1Renal Cell CarcinomaNov 2026
Deciphera PharmaceuticalsDCC-2812
GCN2 activator
GCN2Phase 1Renal Cell CarcinomaFeb 2029

Conditions

Renal Cell Carcinoma (2)

Modalities

small molecule (2)

Companies

Deciphera Pharmaceuticals (1) HiberCell (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.